Translational and reverse-translational research in cancer immunotherapy

FULL PROGRAM

DOWNLOAD PROGRAM

SEPTEMBER 29th
SEPTEMBER 30th

Inscripciones y recogida de documentación

08.30 - 09.00

Presentation / Inauguración

Raimundo Pérez-Hernández y Torra
Mariano Barbacid
Ignacio Melero

08.30 - 09.00

Keynote lectures

Chairs:

Estela Paz. Hospital 12 de Octubre
Miguel Fernández de Sanmamed. CIMA y CUN

09.15 - 11.30

Intravital imaging of immunotherapy

Philippe Bousso. Institut Pasteur. Paris

09.15 – 09.50

Q&A

09.50 – 10.00

Immunotherapy for ovarian cancer

George Coukos. University of Lausanne

10.00 – 10.35

Q&A

10.35 – 10.45

HLA Class-I loss and cancer immune escape

Federico Garrido. University of Granada. Spain

10.45 - 11.20

Q&A

11.20 - 11.30

Break

11.30 – 12.00

SESSION 1

Chair:

Juan José Lasarte. CIMA

12.00 – 13.45

Novel mechanisms of immune escape in HCC

Amaia Lujambio. Icahn School of Medicine at Mount Sinai. NYC

12.00 - 12.30

Natural conventional Dendritic cells and their metabolism in cancer immunotherapy

David Sancho. CNIC. Madrid

12.30 – 13.00

CD137 (4-1BB)-based immunotherapy: 25th anniversary

Ignacio Melero. CIMA y CUN. Spain

13.00 – 13.30

Q&A

13.30 - 13.45

Lunch

13.45 – 15.30

SESSION 2

Chair:

Sandra Hervás. CIMA

15.30 – 17.15

Adoptive T cell therapy in melanoma management

Inge Marie Svane. Center for Cancer Immune Therapy (CCIT). Copenhagen

15:30 –16.00

Innovation in the CAR T cell arena

Sònia Guedan. Hospital Clinic Barcelona. Spain

16.00 – 16.30

Adoptive T cell therapy based on neoantigens

Sthephanie Goff. National Cancer Institute. Bethesda, USA

16.30 – 17.00

Q&A

17.00 – 17.15

Keynote lecture (sponsored by Highlight Therapeutics)

Chair:

Marisol Quintero. Highlight Therapeutics

17.15 – 17.50

Deciphering the mechanisms of cancer immunotherapy

Ira Mellman. Genentech. Los Ángeles

17.15 – 17.50

Q&A

17.50 – 18.00

SESSION 3

Chair:

Antonio González. CUN. Spain

18.00 – 18.35

Neoadjuvant approaches in cancer immunotherapy

Christian Blank. NetherlanChristian Blank. Netherlands Cancer Institute. The Netherlandsds Cancer Institute. The Netherlands

18.00 – 18.30

Q&A

18.30 – 18.35

Keynote lectures

Chair:

Pedro Berraondo. CIMA

9.00 - 10.30

The IL-1 family in cancer inflammation

Alberto Mantovani. Humanitas University. Milan, Italy

9.00 - 9.35

Q&A

9.35 - 9.45

Exploitation of cancer neoantigens

Beatriz Carreño. University of Pennsylvania School of Medicine. USA

9.45 - 10.20

Q&A

10.20 – 10.30

Break

10.30 – 11.00

SESSION 4

Chair:

Christian Blank. Netherlands Cancer Institute. The Netherlands

11.00 – 12.45

Towards clinical development of radioimmunotherapy strategies

María Rodríguez Ruiz. CUN. Spain

11.00 - 11.30

Heterogeneity of immune biomarkers in NSCLC

Crispin Halley. UCL. London

11.30 – 12.00

Combining radiotherapy and immunotherapy

Tim Ilidge. Cancer Research UK Manchester Institute

12.00 – 12.30

Q&A

12.30 - 12.45

SESSION 5

Chair:

Ignacio Melero. CIMA y CUN

12.45 – 13.50

Immunotherapy of hepatocellular carcinoma

Bruno Sangro. CUN. Spain

12.45 – 13.15

NASH and hepatocellular carcinoma-immunotherapy

Mathias Heikenwälder. German Cancer Research Center. Heidelberg, Germany

13.15 – 13.45

Q&A

13.45 – 13.55

Lunch

13.55 – 16.00

SESSION 6

Chair:

Fernando Pastor. CIMA. Spain

16.00 – 17.45

TGFβ in colon cancer immunology

Eduard Batlle. IRB Barcelona. Spain

16.00 – 16.30

LIF in cancer immunology and immunotherapy

Joan Seoane. VHIO. Barcelona, Spain

16.30 – 17.00

Dissecting and modulating anti-cancer immunity in patient-derived tumor fragments

Daniela Thommen. Netherlands Cancer Institute. The Netherlands

17.00 – 17.30

Q&A

17.30 – 17.45

Clínica Universidad de Navarra/CIMA

Translational and reverse-translational research in cancer immunotherapy

Madrid. September. 29th and 30th, 2022

EVENT WILL START IN

FULL PROGRAM

DOWNLOAD PROGRAM

Inscripciones y recogida de documentación

Presentation / Inauguración

Keynote lectures

Chairs:

Intravital imaging of immunotherapy

Q&A

Immunotherapy for ovarian cancer

Q&A

HLA Class-I loss and cancer immune escape

Q&A

Break

SESSION 1

Chair:

Novel mechanisms of immune escape in HCC

Natural conventional Dendritic cells and their metabolism in cancer immunotherapy

CD137 (4-1BB)-based immunotherapy: 25th anniversary

Q&A

Lunch

SESSION 2

Chair:

Adoptive T cell therapy in melanoma management

Innovation in the CAR T cell arena

Adoptive T cell therapy based on neoantigens

Q&A

Keynote lecture (sponsored by Highlight Therapeutics)

Chair:

Deciphering the mechanisms of cancer immunotherapy

Q&A

SESSION 3

Chair:

Neoadjuvant approaches in cancer immunotherapy

Q&A

Keynote lectures

Chair:

The IL-1 family in cancer inflammation

Q&A

Exploitation of cancer neoantigens

Q&A

Break

SESSION 4

Chair:

Towards clinical development of radioimmunotherapy strategies

Heterogeneity of immune biomarkers in NSCLC

Combining radiotherapy and immunotherapy

Q&A

SESSION 5

Chair:

Immunotherapy of hepatocellular carcinoma

NASH and hepatocellular carcinoma-immunotherapy

Q&A

Lunch

SESSION 6

Chair:

TGFβ in colon cancer immunology

LIF in cancer immunology and immunotherapy

Dissecting and modulating anti-cancer immunity in patient-derived tumor fragments

Q&A

ADJOURN

CONTACT

ADDRESS

SEND US A MESSAGE

Madrid. September. 29^thand 30^th, 2022